Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.

RMD Open · 2019 · PMC6397430 · PMID 30886732

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In anti-CCP-/RF+ and anti-CCP-/RF- patients, DAS28-4(ESR) remission rates were numerically higher in those treated with tofacitinib 5 and 10 mg two times a day than in patients treated with placebo; however, these differences did not reach statistical significance ( figure 2A ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.